Company Description
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer.
The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma.
OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine.
The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011.
OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.
On June 14, 2023, OncoSec Medical Incorporated filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Daniel O'Connor |
Contact Details
Address: 820 Bear Tavern Road Ewing, New Jersey 08628 United States | |
| Phone | (858) 210-7333 |
| Website | oncosec.com |
Stock Details
| Ticker Symbol | ONCSQ |
| Exchange | OTCMKTS |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0001444307 |
| ISIN Number | US68234L4059 |
| Employer ID | 98-0573252 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 10, 2023 | 25-NSE | Filing |
| Jun 22, 2023 | 8-K | Current Report |
| Jun 14, 2023 | 8-K | Current Report |
| Jun 14, 2023 | 8-K | Current Report |
| Jun 2, 2023 | 8-K | Current Report |
| May 26, 2023 | D | Notice of Exempt Offering of Securities |
| May 25, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 19, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 18, 2023 | 8-K | Current Report |